GoodRx Holdings (GDRX) Receivables (2019 - 2026)

GoodRx Holdings has disclosed Receivables across 8 years of filings, most recently posting $244.6 million for Q1 2026.

• Receivables for Q1 2026 came in at $244.6 million, up 52.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $244.6 million (up 52.78% YoY), and the FY2025 annual result was $247.6 million, up 69.7% from the prior year.
• Receivables came in at $244.6 million for Q1 2026 at GoodRx Holdings, down from $247.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $247.6 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• The 5-year median for Receivables is $143.6 million (2023), against an average of $154.0 million.
• Across the five-year window, Receivables slipped 5.55% in 2023 and soared 69.7% in 2025, its largest moves.
• GoodRx Holdings' Receivables stood at $117.1 million in 2022, then gained by 22.59% to $143.6 million in 2023, then climbed by 1.62% to $145.9 million in 2024, then jumped by 69.7% to $247.6 million in 2025, then retreated by 1.22% to $244.6 million in 2026.
• The last three Receivables figures came in at $244.6 million (Q1 2026), $247.6 million (Q4 2025), and $203.7 million (Q3 2025), per Business Quant data.